{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T12:18:12Z","timestamp":1790338692903,"version":"4.1.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T00:00:00Z","timestamp":1562025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Merck Sharp & Dohme Corp"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>A conditionally replication-defective human cytomegalovirus (CMV) vaccine (V160) derived from AD169 and genetically engineered to express CMV pentameric complex (gH\/gL\/pUL128\/pUL130\/pUL131) was developed and evaluated for phase 1 vaccine safety and immunogenicity in CMV-seronegative and CMV-seropositive adults.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Subjects received 3 doses of V160 or placebo on day 1, month 1, and month 6. Four vaccine dose levels, formulated with or without aluminum phosphate adjuvant, were evaluated. Injection-site and systemic adverse events (AEs) and vaccine viral shedding were monitored. CMV-specific cellular and humoral responses were measured by interferon-gamma ELISPOT and virus neutralization assay up to 12 months after last dose.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>V160 was generally well-tolerated, with no serious AEs observed. Transient, mild-to-moderate injection-site and systemic AEs were reported more frequently in vaccinated subjects than placebo. Vaccine viral shedding was not detected in any subject, confirming the nonreplicating feature of V160. Robust neutralizing antibody titers were elicited and maintained through 12 months postvaccination. Cellular responses to structural and nonstructural viral proteins were observed, indicating de novo expression of viral genes postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>V160 displayed an acceptable safety profile. Levels of neutralizing antibodies and T-cell responses in CMV-seronegative subjects were within ranges observed following natural CMV infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trial Registration<\/jats:title>\n                  <jats:p>.\u2003NCT01986010.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiz141","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T01:20:54Z","timestamp":1554945654000},"page":"411-419","source":"Crossref","is-referenced-by-count":67,"title":["Phase 1 Clinical Trial of a Conditionally Replication-Defective Human Cytomegalovirus (CMV) Vaccine in CMV-Seronegative Subjects"],"prefix":"10.1093","volume":"220","author":[{"given":"Stuart P","family":"Adler","sequence":"first","affiliation":[{"name":"CMV Research Foundation, Richmond, Virginia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Lewis","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Conlon","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P","family":"Christiansen","sequence":"additional","affiliation":[{"name":"Diablo Clinical Research Inc., Walnut Creek, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Al-Ibrahim","sequence":"additional","affiliation":[{"name":"SNBL Clinical Pharmacology Center, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Rupp","sequence":"additional","affiliation":[{"name":"Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong-Ming","family":"Fu","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Bautista","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Tang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Wang","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Fisher","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Culp","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rituparna","family":"Das","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Beck","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen","family":"Tamms","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5484-7037","authenticated-orcid":false,"given":"Luwy","family":"Musey","sequence":"additional","affiliation":[{"name":"Merck & Co., Inc., Kenilworth, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"V160-001 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,2]]},"reference":[{"key":"2019091820512018100_CIT0001","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1002\/rmv.544","article-title":"New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection","volume":"17","author":"Dollard","year":"2007","journal-title":"Rev Med Virol"},{"key":"2019091820512018100_CIT0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1128\/CMR.00062-12","article-title":"The \u201csilent\u201d global burden of congenital cytomegalovirus","volume":"26","author":"Manicklal","year":"2013","journal-title":"Clin Microbiol Rev"},{"key":"2019091820512018100_CIT0003","volume-title":"Cytomegalovirus (CMV) and congenital CMV infection","author":"Centers for Disease Control and Prevention"},{"key":"2019091820512018100_CIT0004","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1053\/j.spid.2004.09.011","article-title":"Congenital cytomegalovirus infection: outcome and diagnosis","volume":"16","author":"Ross","year":"2005","journal-title":"Semin Pediatr Infect Dis"},{"key":"2019091820512018100_CIT0005","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/rmv.535","article-title":"Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection","volume":"17","author":"Kenneson","year":"2007","journal-title":"Rev Med Virol"},{"key":"2019091820512018100_CIT0006","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/rmv.1797","article-title":"Human cytomegalovirus tropism for mucosal myeloid dendritic cells","volume":"24","author":"Hertel","year":"2014","journal-title":"Rev Med Virol"},{"key":"2019091820512018100_CIT0007","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/S0378-3782(14)70011-8","article-title":"Role of human cytomegalovirus (HCMV)-specific antibody in HCMV-infected pregnant women","volume":"90","author":"Revello","year":"2014","journal-title":"Early Hum Dev"},{"key":"2019091820512018100_CIT0008","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1084\/jem.20050882","article-title":"Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects","volume":"202","author":"Sylwester","year":"2005","journal-title":"J Exp Med"},{"key":"2019091820512018100_CIT0009","volume-title":"EU\/3\/14\/1235.","author":"European Medicines Agency"},{"key":"2019091820512018100_CIT0010","doi-asserted-by":"crossref","first-page":"e02392-16","DOI":"10.1128\/JVI.02392-16","article-title":"Congenital human cytomegalovirus and the enigma of maternal immunity","volume":"91","author":"Britt","year":"2017","journal-title":"J Virol"},{"key":"2019091820512018100_CIT0011","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jama.289.8.1008","article-title":"Maternal immunity and prevention of congenital cytomegalovirus infection","volume":"289","author":"Fowler","year":"2003","journal-title":"JAMA"},{"key":"2019091820512018100_CIT0012","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM199203053261003","article-title":"The outcome of congenital cytomegalovirus infection in relation to maternal antibody status","volume":"326","author":"Fowler","year":"1992","journal-title":"N Engl J Med"},{"key":"2019091820512018100_CIT0013","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3947\/ic.2013.45.3.260","article-title":"Cytomegalovirus infections in solid organ transplantation: a review","volume":"45","author":"Ramanan","year":"2013","journal-title":"Infect Chemother"},{"key":"2019091820512018100_CIT0014","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1093\/infdis\/171.1.26","article-title":"Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age","volume":"171","author":"Adler","year":"1995","journal-title":"J Infect Dis"},{"key":"2019091820512018100_CIT0015","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.vaccine.2014.03.057","article-title":"Progress on pursuit of human cytomegalovirus vaccines for prevention of congenital infection and disease","volume":"32","author":"Fu","year":"2014","journal-title":"Vaccine"},{"key":"2019091820512018100_CIT0016","doi-asserted-by":"crossref","first-page":"7469","DOI":"10.1016\/j.vaccine.2012.10.053","article-title":"Restoration of viral epithelial tropism improves immunogenicity in rabbits and rhesus macaques for a whole virion vaccine of human cytomegalovirus","volume":"30","author":"Fu","year":"2012","journal-title":"Vaccine"},{"key":"2019091820512018100_CIT0017","doi-asserted-by":"crossref","first-page":"362ra145","DOI":"10.1126\/scitranslmed.aaf9387","article-title":"A replication-defective human cytomegalovirus vaccine for prevention of congenital infection","volume":"8","author":"Wang","year":"2016","journal-title":"Sci Transl Med"},{"key":"2019091820512018100_CIT0018","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.cell.2006.07.025","article-title":"A rapid, reversible, and tunable method to regulate protein function in living cells using synthetic small molecules","volume":"126","author":"Banaszynski","year":"2006","journal-title":"Cell"},{"key":"2019091820512018100_CIT0019","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nmeth.1346","article-title":"Conditional and reversible disruption of essential herpesvirus proteins","volume":"6","author":"Glass","year":"2009","journal-title":"Nat Methods"},{"key":"2019091820512018100_CIT0020","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1016\/j.vaccine.2011.08.086","article-title":"A novel high-throughput neutralization assay for supporting clinical evaluations of human cytomegalovirus vaccines","volume":"29","author":"Tang","year":"2011","journal-title":"Vaccine"},{"key":"2019091820512018100_CIT0021","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jviromet.2013.10.036","article-title":"Optimization of interferon gamma ELISPOT assay to detect human cytomegalovirus specific T-cell responses in solid organ transplants","volume":"196","author":"Abate","year":"2014","journal-title":"J Virol Methods"},{"key":"2019091820512018100_CIT0022","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.02.089","article-title":"Vaccination against the human cytomegalovirus","author":"Plotkin","journal-title":"Vaccine"},{"key":"2019091820512018100_CIT0023","doi-asserted-by":"crossref","first-page":"10023","DOI":"10.1128\/JVI.78.18.10023-10033.2004","article-title":"Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes","volume":"78","author":"Hahn","year":"2004","journal-title":"J Virol"},{"key":"2019091820512018100_CIT0024","doi-asserted-by":"crossref","first-page":"18153","DOI":"10.1073\/pnas.0509201102","article-title":"Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism","volume":"102","author":"Wang","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019091820512018100_CIT0025","doi-asserted-by":"crossref","first-page":"11884","DOI":"10.1128\/JVI.01701-15","article-title":"Vaccine-derived neutralizing antibodies to the human cytomegalovirus gH\/gL pentamer potently block primary cytotrophoblast infection","volume":"89","author":"Chiuppesi","year":"2015","journal-title":"J Virol"},{"key":"2019091820512018100_CIT0026","doi-asserted-by":"crossref","first-page":"E4997","DOI":"10.1073\/pnas.1316517110","article-title":"Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine","volume":"110","author":"Freed","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019091820512018100_CIT0027","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/JVI.01809-09","article-title":"Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH\/gL\/UL128-131A complex","volume":"84","author":"Macagno","year":"2010","journal-title":"J Virol"},{"key":"2019091820512018100_CIT0028","doi-asserted-by":"crossref","first-page":"73654","DOI":"10.18632\/oncotarget.18359","article-title":"Active evolution of memory B-cells specific to viral gH\/gL\/pUL128\/130\/131 pentameric complex in healthy subjects with silent human cytomegalovirus infection","volume":"8","author":"Xia","year":"2017","journal-title":"Oncotarget"},{"key":"2019091820512018100_CIT0029","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1016\/j.vaccine.2008.07.092","article-title":"Cytomegalovirus vaccines fail to induce epithelial entry neutralizing antibodies comparable to natural infection","volume":"26","author":"Cui","year":"2008","journal-title":"Vaccine"},{"key":"2019091820512018100_CIT0030","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1086\/512245","article-title":"Development of human cytomegalovirus-specific T cell immunity during primary infection of pregnant women and its correlation with virus transmission to the fetus","volume":"195","author":"Lilleri","year":"2007","journal-title":"J Infect Dis"},{"key":"2019091820512018100_CIT0031","doi-asserted-by":"crossref","first-page":"e59863","DOI":"10.1371\/journal.pone.0059863","article-title":"Fetal human cytomegalovirus transmission correlates with delayed maternal antibodies to gH\/gL\/pUL128-130-131 complex during primary infection","volume":"8","author":"Lilleri","year":"2013","journal-title":"PLoS One"},{"key":"2019091820512018100_CIT0032","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1056\/NEJM200105033441804","article-title":"Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity","volume":"344","author":"Boppana","year":"2001","journal-title":"N Engl J Med"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/220\/3\/411\/30036050\/jiz141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T20:51:41Z","timestamp":1568839901000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/220\/3\/411\/5527176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,2]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,7,2]]},"published-print":{"date-parts":[[2019,7,2]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiz141","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8,1]]},"published":{"date-parts":[[2019,7,2]]}}}